Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection

Moxonidine is the newest, second-generation, centrally acting antihypertensive agent. It has selective agonist activity at imidazoline I1 receptors and less adverse effects than the other centrally acting drugs. This fact authorizes the frequent use of moxonidine in clinical practice, as monotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Karlafti, Eleni F., Hatzitolios, Apostolos I., Karlaftis, Anastasios F., Baltatzi, Maria S., Koliakos, Georgios G., Savopoulos, Christos G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831737/
https://www.ncbi.nlm.nih.gov/pubmed/24302832
http://dx.doi.org/10.4103/0975-7406.120067
_version_ 1782291611711963136
author Karlafti, Eleni F.
Hatzitolios, Apostolos I.
Karlaftis, Anastasios F.
Baltatzi, Maria S.
Koliakos, Georgios G.
Savopoulos, Christos G.
author_facet Karlafti, Eleni F.
Hatzitolios, Apostolos I.
Karlaftis, Anastasios F.
Baltatzi, Maria S.
Koliakos, Georgios G.
Savopoulos, Christos G.
author_sort Karlafti, Eleni F.
collection PubMed
description Moxonidine is the newest, second-generation, centrally acting antihypertensive agent. It has selective agonist activity at imidazoline I1 receptors and less adverse effects than the other centrally acting drugs. This fact authorizes the frequent use of moxonidine in clinical practice, as monotherapy or in combination with other antihypertensive agents. Also, moxonidine has beneficial effects in obese and metabolic syndrome and in target-organs, such as heart and kidneys.
format Online
Article
Text
id pubmed-3831737
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-38317372013-12-03 Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection Karlafti, Eleni F. Hatzitolios, Apostolos I. Karlaftis, Anastasios F. Baltatzi, Maria S. Koliakos, Georgios G. Savopoulos, Christos G. J Pharm Bioallied Sci Review Article Moxonidine is the newest, second-generation, centrally acting antihypertensive agent. It has selective agonist activity at imidazoline I1 receptors and less adverse effects than the other centrally acting drugs. This fact authorizes the frequent use of moxonidine in clinical practice, as monotherapy or in combination with other antihypertensive agents. Also, moxonidine has beneficial effects in obese and metabolic syndrome and in target-organs, such as heart and kidneys. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3831737/ /pubmed/24302832 http://dx.doi.org/10.4103/0975-7406.120067 Text en Copyright: © Journal of Pharmacy and Bioallied Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Karlafti, Eleni F.
Hatzitolios, Apostolos I.
Karlaftis, Anastasios F.
Baltatzi, Maria S.
Koliakos, Georgios G.
Savopoulos, Christos G.
Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection
title Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection
title_full Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection
title_fullStr Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection
title_full_unstemmed Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection
title_short Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection
title_sort effects of moxonidine on sympathetic nervous system activity: an update on metabolism, cardio, and other target-organ protection
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831737/
https://www.ncbi.nlm.nih.gov/pubmed/24302832
http://dx.doi.org/10.4103/0975-7406.120067
work_keys_str_mv AT karlaftielenif effectsofmoxonidineonsympatheticnervoussystemactivityanupdateonmetabolismcardioandothertargetorganprotection
AT hatzitoliosapostolosi effectsofmoxonidineonsympatheticnervoussystemactivityanupdateonmetabolismcardioandothertargetorganprotection
AT karlaftisanastasiosf effectsofmoxonidineonsympatheticnervoussystemactivityanupdateonmetabolismcardioandothertargetorganprotection
AT baltatzimarias effectsofmoxonidineonsympatheticnervoussystemactivityanupdateonmetabolismcardioandothertargetorganprotection
AT koliakosgeorgiosg effectsofmoxonidineonsympatheticnervoussystemactivityanupdateonmetabolismcardioandothertargetorganprotection
AT savopouloschristosg effectsofmoxonidineonsympatheticnervoussystemactivityanupdateonmetabolismcardioandothertargetorganprotection

Ejemplares similares